Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 3-(n-piperidinyl)-1,1-diphenyl-1-propanol Methanesulfonate
2. 3-piperidino-1,1-diphenylpropanol
3. 3-piperidinyl-1,1-diphenylpropan-1-ol
4. Myoson
5. Pridinol Mesylate
6. Pridinol Monohydrochloride
7. Pridinol Monomesylate
8. Ridinol
1. 511-45-5
2. 1,1-diphenyl-3-(piperidin-1-yl)propan-1-ol
3. Nonplesin
4. Lyseen
5. Parks
6. Parks 12
7. Parks 12 Hommel
8. Pridinolum
9. Nonpressin (free Base)
10. C-238
11. Hh 212
12. 1,1-diphenyl-3-piperidino-1-propanol
13. Alpha,alpha-diphenyl-1-piperidinepropanol
14. 1,1-diphenyl-3-(1-piperidyl)-1-propanol
15. 1-piperidinepropanol, Alpha,alpha-diphenyl-
16. 3-(n-piperidyl)-1,1-diphenyl-1-propanol
17. 238 C
18. Nsc 23016
19. Nsc-23016
20. Nsc23016
21. 9e75q6suub
22. 1,1-diphenyl-3-piperidin-1-ylpropan-1-ol
23. 1,1-diphenyl-3-(1-piperidinyl)-1-propanol
24. Ridinol
25. Chebi:75247
26. Pridinol (inn)
27. Pridinol Mesilate
28. Benzhydrol, .alpha.-(2-piperidinoethyl)-
29. Pridinol [inn]
30. Nsc 23016; Nsc 403797; Nonplesin
31. .alpha.,.alpha.-diphenyl-1-piperidinepropanol
32. Dsstox_cid_25090
33. Dsstox_rid_80664
34. Dsstox_gsid_45090
35. Pridinol [inn:dcf]
36. Pridinolum [inn-latin]
37. 1-piperidinepropanol,.alpha.-diphenyl-
38. Cas-511-45-5
39. Hsdb 2684
40. Einecs 208-128-0
41. Unii-9e75q6suub
42. Benzhydrol, Alpha-(2-piperidinoethyl)-
43. Brn 0252983
44. A-carotene
45. Spectrum_001320
46. Pridinol [hsdb]
47. Pridinol [mi]
48. Prestwick0_000799
49. Prestwick1_000799
50. Prestwick2_000799
51. Prestwick3_000799
52. Spectrum2_001985
53. Spectrum3_001552
54. Spectrum4_000728
55. Spectrum5_001069
56. Pridinol [who-dd]
57. Ncistruc1_000328
58. Ncistruc2_000375
59. Bspbio_000938
60. Bspbio_003024
61. Kbiogr_000996
62. Kbioss_001800
63. 5-20-02-00247 (beilstein Handbook Reference)
64. Divk1c_000726
65. Schembl143298
66. Spbio_002169
67. Spbio_002877
68. Bpbio1_001032
69. Chembl404215
70. Dtxsid0045090
71. Kbio1_000726
72. Kbio2_001800
73. Kbio2_004368
74. Kbio2_006936
75. Kbio3_002524
76. Ninds_000726
77. Alpha-(2-piperidinoethyl)benzhydrol
78. Nci23016
79. Zinc1482149
80. Tox21_110022
81. Ccg-37974
82. Mfcd00242961
83. Ncgc00013289
84. Nsc403797
85. Akos016001547
86. Tox21_110022_1
87. Db13642
88. Nsc-403797
89. Idi1_000726
90. Ncgc00013289-01
91. Ncgc00013289-02
92. Ncgc00013289-03
93. Ncgc00013289-04
94. Ncgc00013289-05
95. Ncgc00013289-06
96. Ncgc00013289-07
97. Ncgc00013289-09
98. Ncgc00023906-03
99. Ncgc00023906-04
100. Ncgc00023906-05
101. Ac-24366
102. Nci60_001871
103. Sbi-0051765.p002
104. Ab00053638
105. 1,1-diphenyl-3-piperidin-1-yl-propan-1-ol
106. D08418
107. 1,1-diphenyl-3-(1-piperidinyl)-1-propanol #
108. 1-piperidinepropanol, .alpha.,.alpha.-diphenyl-
109. Ab00053638_16
110. Ab00053638_17
111. N-propanol, 1,1-diphenyl-3-(piperidin-1-yl)-
112. Ag-680/20240026
113. Q827515
114. Brd-k17565903-066-05-8
115. Brd-k17565903-066-15-7
Molecular Weight | 295.4 g/mol |
---|---|
Molecular Formula | C20H25NO |
XLogP3 | 3.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 5 |
Exact Mass | 295.193614421 g/mol |
Monoisotopic Mass | 295.193614421 g/mol |
Topological Polar Surface Area | 23.5 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 294 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
/EXPL THER/ A randomized, double-blind, placebo-controlled three-way cross-over study was performed to investigate the effect of two muscle relaxants (tolperisone hydrochloride and pridinol mesilate) on experimental jaw-muscle pain and jaw-stretch reflexes. Fifteen healthy men participated in three randomized sessions separated by at least 1 week. In each session 300 mg tolperisone, 8 mg pridinol mesilate or placebo was administered orally as a single dose. One hour after drug administration 0.3 mL hypertonic saline (5.8%) was injected into the right masseter to produce muscle pain. Subjects continuously rated their perceived pain intensity on an electronic 10-cm visual analogue scale (VAS). The pressure pain threshold (PPT) was measured and short-latency reflex responses were evoked in the pre-contracted (15% maximal voluntary contraction) masseter and temporalis muscles by a standardised stretch device (1 mm displacement, 10 ms ramp time) before (baseline), 1 hr after medication (post-drug), during ongoing experimental muscle pain (pain-post-drug), and 15 min after pain had vanished (post-pain). Analysis of variance demonstrated significantly lower VAS peak pain scores (5.9 +/- 0.4 cm) after administration of tolperisone hydrochloride compared with pridinol mesilate (6.8 +/- 0.4 cm) and placebo (6.6 +/- 0.4 cm) (P=0.020). Administration of pridinol mesilate was associated with a significant decrease in PPTs compared with tolperisone hydrochloride and placebo (P=0.002) after medication, but not after experimental jaw-muscle pain. The normalized peak-to-peak amplitude of the stretch reflexes were not significantly influenced by the test medication (P=0.762), but were in all sessions significantly facilitated during ongoing experimental jaw-muscle pain (P=0.034). In conclusion, tolperisone hydrochloride provides a small, albeit significant reduction in the perceived intensity of experimental jaw-muscle pain whereas the present dose had no effect on the short-latency jaw-stretch reflex. /Tolperisone hydrochloride and pridinol mesilate/
PMID:12935797 Svensson P et al; Eur J Pain 7 (5): 449-56 (2003)
M - Musculo-skeletal system
M03 - Muscle relaxants
M03B - Muscle relaxants, centrally acting agents
M03BX - Other centrally acting agents
M03BX03 - Pridinol
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
Reply
14 Sep 2024
Reply
15 Jun 2023
Reply
28 Mar 2023
Reply
19 Jan 2023
Reply
23 Nov 2022
Reply
17 Nov 2022
Reply
08 Mar 2022
Reply
20 Aug 2021
Reply
29 May 2021
Reply
24 Sep 2020
ANALYTICAL
ABOUT THIS PAGE
55
PharmaCompass offers a list of Pridinol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pridinol manufacturer or Pridinol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pridinol manufacturer or Pridinol supplier.
PharmaCompass also assists you with knowing the Pridinol API Price utilized in the formulation of products. Pridinol API Price is not always fixed or binding as the Pridinol Price is obtained through a variety of data sources. The Pridinol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pridinol mesilate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pridinol mesilate, including repackagers and relabelers. The FDA regulates Pridinol mesilate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pridinol mesilate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pridinol mesilate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pridinol mesilate supplier is an individual or a company that provides Pridinol mesilate active pharmaceutical ingredient (API) or Pridinol mesilate finished formulations upon request. The Pridinol mesilate suppliers may include Pridinol mesilate API manufacturers, exporters, distributors and traders.
click here to find a list of Pridinol mesilate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pridinol mesilate DMF (Drug Master File) is a document detailing the whole manufacturing process of Pridinol mesilate active pharmaceutical ingredient (API) in detail. Different forms of Pridinol mesilate DMFs exist exist since differing nations have different regulations, such as Pridinol mesilate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pridinol mesilate DMF submitted to regulatory agencies in the US is known as a USDMF. Pridinol mesilate USDMF includes data on Pridinol mesilate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pridinol mesilate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pridinol mesilate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pridinol mesilate Drug Master File in Japan (Pridinol mesilate JDMF) empowers Pridinol mesilate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pridinol mesilate JDMF during the approval evaluation for pharmaceutical products. At the time of Pridinol mesilate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pridinol mesilate suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pridinol mesilate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pridinol mesilate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pridinol mesilate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pridinol mesilate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pridinol mesilate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pridinol mesilate suppliers with NDC on PharmaCompass.
Pridinol mesilate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pridinol mesilate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pridinol mesilate GMP manufacturer or Pridinol mesilate GMP API supplier for your needs.
A Pridinol mesilate CoA (Certificate of Analysis) is a formal document that attests to Pridinol mesilate's compliance with Pridinol mesilate specifications and serves as a tool for batch-level quality control.
Pridinol mesilate CoA mostly includes findings from lab analyses of a specific batch. For each Pridinol mesilate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pridinol mesilate may be tested according to a variety of international standards, such as European Pharmacopoeia (Pridinol mesilate EP), Pridinol mesilate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pridinol mesilate USP).